Asia300

Lupin Ltd.

India

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
May 26, 2017
Prev close: 1,111.9
May 26, 2017
Market cap:
Market cap(USD):
502,213M
7,794.71M
Shares: 451.67M

Currency in INR

Company profile

Market(Ticker): BOM(500257)
Sector:
Industry:
Health Technology
Pharmaceuticals: Generic
Full time employees: --

Business summary

Lupin Ltd. operates as a pharmaceuticals company, which manufactures and distributes pharmaceutical ingredients and formulations. It offers products in growth therapy segments, such as cardiology, central nervous system, anti-diabetic, anti-TB, anti-asthma, gynaecology, anti-infective, gastro-intestinal and others. Lupin was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Company background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 174,943.3M
Gross profit 110,412.4M
Operating income 37,367.9M
Income before tax 35,348.9M
Net income 25,574.6M
EBITDA 46,490.2M
Diluted EPS 56.46
Dividends per share --
Total assets 266,072.8M
Total liabilities 130,751.9M
Total equity 134,975.7M
Operating cash flow --

Currency in INR

Revenue 2,608.87M
Gross profit 1,646.54M
Operating income 557.25M
Income before tax 527.14M
Net income 381.38M
EBITDA 693.29M
Diluted EPS 0.84
Dividends per share --
Total assets 4,097.52M
Total liabilities 2,013.58M
Total equity 2,078.62M
Operating cash flow --

Currency in USD

Valuation measures

Mar 2017

PER 25.48
ROA 10.40%
ROE 20.89%
Operating margin 21.36%
Profit margin 14.61%

Key executive

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita Gupta Sharma
  • Chief Financial Officer & Executive Director: Ramesh Swaminathan
  • Secretary & Compliance Officer: Rajvardhan V. Satam
  • Group President-India Region Formulations & CIS: Shakti Chakraborty

Share holders

  • Zyma Laboratories Ltd.(12.3%)
  • Rahas Investments Ltd.(10.2%)
  • Visiomed Investments Pvt. Ltd.(9.7%)
  • Lupin Holdings Pvt. Ltd.(9.0%)
  • Lupin Investments Pvt Ltd.(3.4%)
  • First State Investment Management (UK) Ltd.(2.6%)
  • Genesis Investment Management LLP(2.3%)
  • JHUNJHUNWALA RAKESH RADHESHYAM(1.7%)
  • GIC Pte Ltd. (Investment Management)(1.6%)
  • The Vanguard Group, Inc.(1.6%)

Address

  • Website: http://www.lupinworld.com
  • Address: B/4 Laxmi Towers, Bandra (East), Mumbai, 400051, India
  • Phone: +91.22.66402222

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.